Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 3
1992 4
1993 1
1994 7
1995 17
1996 12
1997 7
1998 2
1999 10
2000 10
2001 19
2002 16
2003 9
2004 3
2005 1
2007 2
2008 2
2009 4
2010 1
2013 1
2015 1
2016 3
2017 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Remacemide for drug-resistant localization related epilepsy.
Leach JP, Marson AG, Hutton JL. Leach JP, et al. Cochrane Database Syst Rev. 2002;(4):CD001900. doi: 10.1002/14651858.CD001900. Cochrane Database Syst Rev. 2002. PMID: 12519561 Review.
In response to this problem, potential new drugs are being developed. Remacemide is one of these. OBJECTIVES: To evaluate the effects of add-on treatment with remacemide upon seizures, adverse effects, cognition and quality of life for people with drug-resistant loc …
In response to this problem, potential new drugs are being developed. Remacemide is one of these. OBJECTIVES: To evaluate the effects …
Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat.
Garske GE, Palmer GC, Napier JJ, Griffith RC, Freedman LR, Harris EW, Ray R, McCreedy SA, Blosser JC, Woodhead JH, et al. Garske GE, et al. Epilepsy Res. 1991 Sep;9(3):161-74. doi: 10.1016/0920-1211(91)90050-p. Epilepsy Res. 1991. PMID: 1660399
In this context (-)stereoisomer (FPL 14145) was of equal potency to the racemate (remacemide), while the (+)stereoisomer (FPL 14144) was 54% less potent. ...In naive rats high doses of remacemide or its (-)isomer and low doses of phenobarbital caused an increase in …
In this context (-)stereoisomer (FPL 14145) was of equal potency to the racemate (remacemide), while the (+)stereoisomer (FPL 14144) …
Remacemide hydrochloride: a novel antiepileptic agent.
Davies JA. Davies JA. Gen Pharmacol. 1997 Apr;28(4):499-502. doi: 10.1016/s0306-3623(96)00280-7. Gen Pharmacol. 1997. PMID: 9147015 Review.
1. Remacemide hydrochloride has been shown to possess anticonvulsant activity in a wide range of animal models of epilepsy with ED50s in the 6-60 mg/kg range, depending on the species and route of administration. ...Remacemide and its metabolite, in common with othe …
1. Remacemide hydrochloride has been shown to possess anticonvulsant activity in a wide range of animal models of epilepsy with ED50s …
Behavioral effects associated with chronic ketamine or remacemide exposure in rats.
Wright LK, Pearson EC, Hammond TG, Paule MG. Wright LK, et al. Neurotoxicol Teratol. 2007 May-Jun;29(3):348-59. doi: 10.1016/j.ntt.2006.12.004. Epub 2007 Jan 16. Neurotoxicol Teratol. 2007. PMID: 17291718
The effects of chronic exposure to ketamine or remacemide on the acquisition and performance of food-reinforced operant behaviors was assessed in female Sprague-Dawley rats. ...While chronic treatment with either high-dose ketamine or low-dose remacemide only delaye …
The effects of chronic exposure to ketamine or remacemide on the acquisition and performance of food-reinforced operant behaviors was …
Remacemide--a novel potential antiepileptic drug.
Małek R, Borowicz KK, Kimber-Trojnar Z, Sobieszek G, Piskorska B, Czuczwar SJ. Małek R, et al. Pol J Pharmacol. 2003 Sep-Oct;55(5):691-8. Pol J Pharmacol. 2003. PMID: 14704464 Free article. Review.
The aim of this review was to assemble current literature data on remacemide, a novel AED, which is suggested for the treatment of epilepsy. Remacemide hydrochloride is a low-affinity NMDA receptor blocker as well as Na(+) fast-channel blocker. ...
The aim of this review was to assemble current literature data on remacemide, a novel AED, which is suggested for the treatment of ep …
Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice.
Stagnitto ML, Palmer GC, Ordy JM, Griffith RC, Napier JJ, Becker CN, Gentile RJ, Garske GE, Frankenheim JM, Woodhead JH, et al. Stagnitto ML, et al. Epilepsy Res. 1990 Sep-Oct;7(1):11-28. doi: 10.1016/0920-1211(90)90050-6. Epilepsy Res. 1990. PMID: 1963406
An intermediate potency against either audiogenic- or N-methyl-D-aspartate-induced seizures was exhibited by remacemide. Tolerance to MES was not apparent after 5 days of oral daily dosing of remacemide. ...Therapeutic utility for generalized tonic/clonic seizures i …
An intermediate potency against either audiogenic- or N-methyl-D-aspartate-induced seizures was exhibited by remacemide. Tolerance to …
Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant.
Heyn H, McCarthy DJ, Curry SH, Eisman MS, Anders MW. Heyn H, et al. Drug Metab Dispos. 1994 May-Jun;22(3):443-6. Drug Metab Dispos. 1994. PMID: 8070322
The BUI of [14C] remacemide and [14C]FPL12495 were not affected by increasing amounts of unlabeled remacemide or FPL12495, respectively. ...A mixture of [3H]remacemide hydrochloride (3H label in the glycine moiety) and [14C]remacemide hydrochloride (14 …
The BUI of [14C] remacemide and [14C]FPL12495 were not affected by increasing amounts of unlabeled remacemide or FPL12495, res …
Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock.
Borowicz KK, Malek R, Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Borowicz KK, et al. Epilepsy Behav. 2007 Aug;11(1):6-12. doi: 10.1016/j.yebeh.2007.04.018. Epub 2007 Jun 29. Epilepsy Behav. 2007. PMID: 17602881
Although brain valproate concentrations were unaffected by remacemide co-administration, brain concentrations of remacemide and its active metabolite, desglycinyl-remacemide, were increased by 68 and 162%, respectively. In contrast, phenobarbital co-administr …
Although brain valproate concentrations were unaffected by remacemide co-administration, brain concentrations of remacemide an …
A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment.
Devinsky O, Vazquez B, Faught E, Leppik IE, Pellock JM, Schachter S, Alderfer V, Holdich TA. Devinsky O, et al. Seizure. 2002 Sep;11(6):371-6. doi: 10.1053/seiz.2001.0669. Seizure. 2002. PMID: 12160664 Free article. Clinical Trial.
Remacemide and desglycinyl metabolite levels were lower in patients receiving concomitant carbamazepine or phenytoin than in those receiving non-inducing AEDs or remacemide hydrochloride alone. No serious adverse events occurred; all patients receiving remacemide …
Remacemide and desglycinyl metabolite levels were lower in patients receiving concomitant carbamazepine or phenytoin than in those re …
Remacemide: current status and clinical applications.
Schachter SC, Tarsy D. Schachter SC, et al. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83. doi: 10.1517/13543784.9.4.871. Expert Opin Investig Drugs. 2000. PMID: 11060716 Review.
Remacemide (RMC) is a non-competitive, low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist that does not cause the behavioural and neuropathological side effects seen with other NMDA receptor antagonists. ...
Remacemide (RMC) is a non-competitive, low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist that does not cause the behaviour …
137 results